These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 26838696)

  • 1. Treatment of von Willebrand Disease.
    Curnow J; Pasalic L; Favaloro EJ
    Semin Thromb Hemost; 2016 Mar; 42(2):133-46. PubMed ID: 26838696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring Therapy during Treatment of von Willebrand Disease.
    Favaloro EJ; Pasalic L; Curnow J
    Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between VWF and FVIII in treating VWD.
    Miesbach W; Berntorp E
    Eur J Haematol; 2015 Nov; 95(5):449-54. PubMed ID: 25605439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M; Mannucci PM
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
    Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
    J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards novel treatment options in von Willebrand disease.
    Lenting PJ; Kizlik-Manson C; Casari C
    Haemophilia; 2022 May; 28 Suppl 4():5-10. PubMed ID: 35521728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
    Mohammed S; Favaloro EJ
    Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.
    Peyvandi F; Kouides P; Turecek PL; Dow E; Berntorp E
    Blood Rev; 2019 Nov; 38():100572. PubMed ID: 31229334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting von Willebrand disease: the current status and future directions of management therapies.
    Franchini M; Focosi D
    Expert Rev Hematol; 2023; 16(11):871-878. PubMed ID: 37800892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
    Federici AB; Mannucci PM
    Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
    Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
    Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.